trial

Neuromodulation for Schizophrenia

NCTId NCT05580211
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Recruiting
Enrollment 34 (estimated)
Sponsored by Scion NeuroStim
Primary completion 2025-10-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Recruiting
Enrollment
34 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2023-10-03
Primary completion
2025-10-30
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Non-invasive brainstem modulation device (stimulation Randomized)Non-invasive brainstem modulation device (stimulation-Open Label)

Sponsors

Scion NeuroStimLead Sponsor
Centre for Addiction and Mental HealthCollaborator

Sites

1 total
Toronto, Canada

Facts & assertions

4 sourced
Enrollment
34
Phase
NA
Primary Completion Date
2025-10-30
Status
RECRUITING
relationships
The graph out of here
drug
Non-invasive brainstem modulation device (stimulation Randomized)
drug
Non-invasive brainstem modulation device (stimulation-Open Label)
drug
lead_sponsor
Scion NeuroStim
company
collaborator
Centre for Addiction and Mental Health
company
indication
Schizophrenia
indication
Schizophrenia
indication